OncoMatch

OncoMatch/Clinical Trials/NCT06491680

Cardiotoxicity in Breast Cancer Patients

Is NCT06491680 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Dapagliflozin 10mg Tab for breast cancer.

Phase 4RecruitingHelwan UniversityNCT06491680Data as of Jun 2026Location: Egypt

Treatment: Dapagliflozin 10mg TabThe goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug. Aim of the study: Evaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity. The main questions it aims to answer are: 1. Does the drug lower the cardiotoxicity which induced by anthracyclines? 2. What medical problems do participants have when taking dapagliflozin drug? Treatment 1. Anthracyclines by 4 cycles included doxorubicin 50-60 mg/m2 with cyclophosphamide 600 mg as a combination or epirubicin 90-100 mg/m2 with cyclophosphamide 600 mg as a combination. 2. Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Dapagliflozin 10mg Tab

Cancer type

Breast Carcinoma

Demographics

Ages ≤ 60

Prior therapy

Cannot have received: anthracycline-containing regimen

Previous anthracycline-containing regimens

Cannot have received: cardiotoxic chemotherapy

any cardiotoxic chemotherapy regimens

Lab requirements

Kidney function

egfr > 30 ml/minute per 1.73 m2

Cardiac function

lvef > 50%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06491680 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior anthracycline-containing regimen, cardiotoxic chemotherapy disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 60 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify